The Growing STI Concern
In 2023, the United States saw over 2.4 million newly reported cases of chlamydia, gonorrhea, and syphilis—the highest annual total on record—though signs suggest the epidemic may be stabilizing [cdc.gov]. Gonorrhea cases declined 7% from 2022, dipping back to pre‑pandemic levels, while overall syphilis rose just 1%, and primary and secondary syphilis actually fell 10%, marking the first significant drop in over 20 years. Yet, despite these small victories, the sheer volume of infections reminds us that Sexually transmitted infections (STIs) remain a pressing public health issue.
What Are STIs?
Sexually transmitted infections (STIs) are caused by bacteria, viruses, or parasites spread primarily through sexual contact—vaginal, anal, or oral. Common bacterial STIs include:
-
Chlamydia (Chlamydia trachomatis)
-
Gonorrhea (Neisseria gonorrhoeae)
-
Syphilis (Treponema pallidum)
Protozoan infections such as trichomoniasis affect women more often, though men can carry the parasite asymptomatically. Viral STIs include herpes simplex virus (HSV), human papillomavirus (HPV), HIV, and the hepatitis viruses A, B, and C.
Recognizing the Signs—and the Silent Cases
Symptoms vary by infection but often include:
-
New rashes or sores around the genitals or other body parts
-
Unusual discharge from the penis, vagina, or anus
-
Swollen lymph nodes, fever, or general malaise
However, many STIs are asymptomatic, meaning you could be infected without knowing it. Chlamydia, for example, affects an estimated 1.6 million people annually in the U.S. but may only cause symptoms in 5–30% of cases [jwatch.org]. Likewise, Mycoplasma genitalium often flies under the radar due to subtle or absent symptoms.
Why Are STI Rates Rising?
Several interconnected factors fuel the resurgence of STIs:
-
Inconsistent Barrier Use:
Condoms and dental dams reduce STI transmission but are not used consistently. Surveys show that many individuals—across age groups and genders—skip barriers during sex. -
Evolving Attitudes Toward HIV:
Advances like undetectable = untransmissible (U = U) messaging for HIV and pre-exposure prophylaxis (PrEP) have transformed HIV risk perceptions. While these strategies are life‑saving, they may inadvertently lower vigilance around other STIs. -
Cuts to Public Health Funding:
Federal and state budget reductions have shuttered clinics and scaled back screening programs. Restrictions on organizations like Planned Parenthood further limit access to affordable testing and treatment. -
Gaps in Multisite Screening:
Traditional genital testing misses infections in the throat or rectum. A Rhode Island clinic’s review of 2,627 women found that 19% of chlamydia and gonorrhea infections would have been overlooked with genital testing alone [cdc.gov]. Comprehensive sexual history and multisite sampling are critical, especially for individuals engaging in oral or anal sex.
Who Should Get Tested—and When
The U.S. Preventive Services Task Force (USPSTF) recommends routine screening for:
-
Sexually active young women (under 25)
-
Men who have sex with men
-
Anyone with new or multiple partners, or those who share injection equipment
But if you experience any symptoms—or if you’re simply concerned after unprotected contact—it’s wise to get tested. Many local health departments offer free, confidential testing; you can find a clinic using the CDC’s testing locator here.
Taking Prevention Seriously
Preventing STIs isn’t just about avoiding infection; it’s about empowering yourself and your partners:
-
Open Communication: Share your sexual history and testing status honestly with partners and providers.
-
Barrier Methods: Use condoms or dental dams for oral, anal, and vaginal sex every time.
-
Routine Check‑Ups: Incorporate STI testing into regular health exams—ideally every 3–6 months if you have new or multiple partners.
-
Vaccinations: HPV vaccines protect against strains linked to cervical, anal, and oropharyngeal cancers. Hepatitis A and B vaccines guard against two more sexually transmissible viruses.
-
Consider PrEP: If you’re at risk for HIV, daily PrEP can reduce your chance of infection by over 99%.
For those diagnosed with chlamydia or gonorrhea, expedited partner therapy—whereby you receive medication or prescriptions to give directly to partners—can curb reinfection and further spread.
The Road Ahead: Hope and Challenges
While the small declines in gonorrhea and primary syphilis are encouraging, the overall burden of STIs remains unacceptably high. Congenital syphilis—syphilis passed from mother to child during pregnancy—rose in many regions in 2023, underscoring the need for prenatal screening and treatment [apnews.com].
Moving forward, sustained funding for public health programs, expansion of at‑home testing kits, and destigmatization of sexual health conversations are vital. Innovative interventions such as online partner notification services and mobile health apps show promise in reaching underserved populations.
Final Thoughts
Sexually transmitted infections are preventable, treatable, and—most importantly—manageable with the right tools and knowledge. By staying informed of the latest CDC data, committing to honest communication, and taking advantage of available prevention strategies, you can significantly reduce your risk and contribute to broader public health efforts.
For more detailed information, visit the CDC’s Sexually Transmitted Infections Surveillance page or explore patient‑focused resources at TheBody.com.
Sources:
